The prescription drug supply chain in the United States has never been simple. A patient’s medication may pass through manufacturers, wholesalers, pharmacy benefit managers (PBMs), and retail pharmacies before it ever reaches the counter. At each step, another party takes a margin, controls access, or slows the transaction down.
That friction is old news. What’s novel is that now a handful of companies have decided to bypass the supply chain entirely. Instead of negotiating with every intermediary, they are collapsing the entire process into a single business: find the patient, prescribe the drug, fill the prescription, and keep the patient coming back.
In practice, that means replacing a fragmented chain with a single platform. A patient may discover a treatment through an online ad, complete a clinical intake, consult with a licensed provider, receive a prescription, and have the medication shipped directly to their home. The company facilitating that process may control the marketing channel, the provider network, and the dispensing pharmacy itself. Rather than handing the patient off between multiple organizations, the entire experience stays inside one system.
This is the core of the D2C (direct-to-consumer) pharma model: acquire the patient, prescribe the medication, fill the order, and manage the refill. The companies leading the space are not simply selling drugs online. They are reorganizing how medications reach patients by collapsing the distance between finding a patient and treating one.
The global telehealth market reached $161.64 billion in 2024 and is projected to grow at a 22.94% compound annual rate through 2032 (Fortune Business Insights). In the United States, 86.3 million adults used telehealth in 2025, up from 83.3 million in 2024 (Statista). Consumer behavior is moving in the same direction: 38% of Americans have purchased medication online, and 73% of those buyers started doing so within the last three years (SingleCare).
The capital has followed. Roughly $6.1 billion has been invested in D2C pharmaceutical models. Much of that money has gone to companies that look less like traditional drugmakers and more like healthcare infrastructure platforms.
The first categories were not random. Weight loss, hair loss, dermatology, and sexual health all share the same business profile: chronic, recurring, often cash-pay, and relatively light on the prior-authorization complexity that defines much of specialty pharmacy.
Cash-pay care is the key to it all. Without insurers and pharmacy benefit managers (PBMs) sitting between the company and the patient, operators can focus on pricing, retention, and repeat business instead of reimbursement cycles and formulary negotiations.
Chronic conditions make the model even stronger. GLP-1 prescriptions and hair loss treatments are recurring transactions. The subscription dynamic turns expensive customer acquisition into a longer-term revenue stream, which is what compensates for the heavy marketing spend behind these platforms.
___________________________________________________________________________________
Given those economics, weight-loss medications have become the clearest example of how the model scales. GLP-1 drugs sit at the intersection of high consumer demand, recurring treatment, and a willingness among many patients to pay out of pocket for convenience. Telehealth consultations for GLP-1s increased 300% year over year in 2025. Goldman Sachs has projected 15 million U.S. adults on anti-obesity medications by 2030, with the market reaching $100 billion annually (Goldman Sachs Research). UBS has projected an even larger patient base, estimating 40 million people on GLP-1 medications by 2029.
The companies positioned for that volume have moved quickly. Hims & Hers reported 59% year-over-year revenue growth in 2025 and has projected $2.7 billion to $2.9 billion in 2026 revenue. Ro, which began as a men’s health platform, has shifted heavily toward GLP-1 services and carries a $7.19 billion valuation.
Both companies own or operate pharmacy infrastructure. Both have built clinical networks. Their advantage is not only digital convenience, but control as well.
Amazon is approaching the same idea from a different direction. It began with the acquisition of PillPack, built Amazon Pharmacy, acquired One Medical, and has started testing prescription kiosks inside One Medical locations. The entry point is different from Hims or Ro, but the destination is similar: control more of the path from clinical encounter to dispensing.
The model isn’t without its costs. Customer acquisition remains expensive. GLP-1 injectables require cold-chain logistics at the consumer scale. Established pharmaceutical brands also face channel conflict if they move too aggressively into direct distribution and weaken their retail or payer relationships. The companies that have grown fastest have generally chosen categories where cash-pay demand and recurring revenue can absorb those costs.
That calculation may become harder as D2C platforms move into more complex disease areas, insurance-covered drugs, or specialty medications. The model works best when the company can control price, patient access, and fulfillment. The more a category depends on payers, formularies, and reimbursement rules, the more the traditional system reappears.
Regulation Has Not Caught Up
The same integration that makes these companies efficient also creates regulatory tension.
The most obvious issue is the relationship between prescribing and dispensing. In a traditional setting, the prescriber and the pharmacy are usually separate economic actors. In the D2C model, the company that markets the treatment may also employ or contract with the provider and operate the pharmacy that fills the prescription.
That structure creates a different incentive system. More prescriptions can mean more pharmacy revenue. More refills can mean more recurring revenue. Regulators will increasingly ask whether those economics influence clinical decision-making, especially in high-demand categories like weight loss, sexual health, mental health, and controlled substances.
Licensing is another constraint. Physicians and nurse practitioners are licensed at the state level, and providers generally cannot prescribe across state lines without the proper license. The Interstate Medical Licensure Compact and Nurse Licensure Compact have expanded provider mobility, but coverage is incomplete. A national D2C company needs either a provider network that maps to state-by-state rules or a compliance operation capable of managing that complexity.
Controlled substances add another layer. Pandemic-era emergency authorities allowed broader telehealth prescribing of certain Schedule III and IV medications. The DEA’s final rules will shape how far D2C platforms can go in categories that involve controlled drugs (U.S. DEA Telemedicine Rules).
None of this has stopped investment. It does, however, create execution risk that revenue forecasts can overlook. A platform may scale like software, but it is still operating inside healthcare law, pharmacy law, corporate practice of medicine rules, state licensing regimes, and federal controlled-substance regulations.
Where the Model Goes Next
A 2026 Guidehouse analysis put the strategic challenge plainly. “Pharma firms must reclaim the patient relationship — not just to promote products, but to drive end-to-end care coordination.”
The companies moving fastest on that idea are not traditional pharma firms. They are platforms built around the patient transaction: acquisition, consultation, prescription, payment, fulfillment, and refill.
That may become more complicated as GLP-1 coverage expands through employers and eventually Medicare. The cash-pay insulation that helped D2C platforms avoid PBMs and formularies will erode in some categories. The companies that grew by routing around the traditional chain may need to operate alongside it.
Still, the strategic advantage remains ownership. A traditional manufacturer may own the drug. A PBM may control access. A retail pharmacy may own the counter. A D2C platform owns the relationship from the first ad impression to the next refill.
That is why the model matters. The pharmacy is no longer just a dispensing endpoint. In the D2C model, it is part of a larger platform, and the companies that control that platform are changing the economics of medication delivery.
This material has been prepared for informational purposes only, and is not intended to provide or be relied upon for legal or tax advice. If you have any specific legal or tax questions regarding this content or related issues, please consult with your professional legal or tax advisor.
